Parts C, D, and E: patients who have received prior ipilimumab are not eligible
Patients must not have received prior systemic treatment for this melanoma
Patients having received palliative radiotherapy for extracranial metastasis(es) are eligible as long as there are 2 cancerous deposits that have not received prior radiation therapy (RT) and they meet the following criteria\r\n* No prior radiation therapy (> 5 Gy) to the metastasis intended to be treated with SBRT
Patients must not have received enzyme–inducing anticonvulsants within 14 days prior to enrollment
Prior lapatinib is allowed as long as the last dose received was > 21 days prior to study entry and provided the patient has not received it at any time after the diagnosis of brain metastasis
Prior treatment. Patients must have received:
Patients are not required to have received or progressed on a prior therapy.
Patients who have received prior ipilimumab treatment for metastatic melanoma are not eligible.
Subjects who have received prior therapy with any hypomethylating agents
Received prior treatment with radioimmunotherapy, (e.g. radionuclides, holmium).
Phase 1: Subjects with a RET rearrangement must have had disease progression after at least one prior line of systemic therapy; subjects with an ALK rearrangement may be either treatment naive or may have received prior treatment, and must have CNS disease present at baseline; subjects cannot have received more than one prior RET TKI (such as, but not limited to, vandetanib, sorafenib, sunitinib, ponatinib, or cabozantinib); subjects enrolling to the phase 1 portion of the trial must not have received prior alectinib therapy
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy prior to participating in this trial\r\n* No prior myelosuppressive chemotherapy for at least 21 days prior to study enrollment\r\n* Must not have received craniospinal radiation therapy within 24 weeks prior to study entry and no involved field radiation therapy for 12 weeks prior to study enrollment\r\n* If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation\r\n* No investigational drugs for 4 weeks prior to study enrollment\r\n* No prior therapy with mTOR inhibitors (including sirolimus, temsirolimus or everolimus)
PHASE I SUBJECTS ONLY: Prior therapy is allowed; for patients enrolled in the Phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be allowed, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression
Patients who have received any steroids in the week prior to diagnosis except as stated in Section 4.1.4 of the protocol.
Patients can have received any number of prior therapies for treatment of their uveal melanoma excluding prior treatment with an ERK inhibitor; patients who have received prior MEK inhibition or other MAPK targeted agents will be allowed on study
Patients who received prior anti-tumoral radionuclide therapy (with unsealed sources) are not eligible for the study
Has received prior radiotherapy within 2 weeks of start of study therapy or received lung radiation therapy of >30 Gray (Gy) within 6 months of the first dose of study therapy
Patients may be newly diagnosed or have received any number of lines of prior anticancer therapy; however, patients are required to have received available therapies for their primary disease, as deemed appropriate by the treating investigator
Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis
Patients must not have received prior exposure to VX15/2503
Patients may have had treatment (chemotherapy and/or radiotherapy) or no treatment for any number of relapses prior to this recurrence\r\n* Patients must have received their last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks of nitrosourea\r\n* Patients must have received their last dose of other investigational or biological agent > 7 days prior to study entry\r\n** For agents that have known adverse events occurring beyond 7 days after administration, this period should be extended beyond the time during which adverse events are known to occur; this should be discussed with the study chair\r\n* If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation; these patients should also be discussed with the study chair\r\n* Patients must have received their last fraction of craniospinal or focal radiation to primary tumor or other sites > 12 weeks (3 months) prior to registration
Patients with NF1 will only be eligible if complete tumor resection is not considered to be feasible without substantial risk or morbidity, or if a patient with a surgical option refuses surgery\r\n* Since there is no standard effective chemotherapy for patients with NF1 and PN, patients may be treated on this trial without having received prior medical therapy directed at their PN\r\n* Since selumetinib is not expected to cause substantial myelosuppression, there will be no limit to number of prior myelosuppressive regimen for PN or other tumor manifestations associated with NF1 such as optic glioma\r\n* Patients who have received previous investigational agents or biologic therapy, such as tipifarnib, pirfenidone, Peg-Intron, sorafenib, or other VEGFR inhibitors are eligible for enrollment\r\n* Growth factors that support platelet or white cell number or function must not have been administered within the past 7 days and are not permitted while on the study\r\n* At least 6 weeks must have elapsed prior to enrollment since the patient received any prior radiation therapy, and no prior radiation therapy should have been directed at the target PN\r\n* At least 4 weeks must have elapsed since receiving medical therapy directed at the PN\r\n* At least 4 weeks must have elapsed since any surgeries, with evidence of completed wound healing\r\n* Patients who received prior medical therapy for their PN must have recovered from the acute toxic effects of all prior therapy to =< grade 1 Common Terminology Criteria for Adverse Events version 4 (CTCAE v4) before entering this study
Patients will be excluded from Arms A and C if they have received a previous myeloablative transplant; patients who have received a prior HCT at least 6 months prior may be considered for inclusion on Arms B or D after discussion with the principal investigator (PI)
Received prior treatment targeting the signaling pathway of TGF-?.
Patients who have received prior systemic therapy for metastatic RCC or have previously received IL-2 are not eligible; patients on hydroxychloroquine (HCQ) in neoadjuvant protocols or in the past for clinical indications ARE eligible
Subjects must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet time restrictions from end of prior therapy as stated below: \r\n* Myelosuppressive chemotherapy: Subjects must have received the last dose of myelosuppressive therapy at least 3 weeks prior to study registration or at least 6 weeks if therapy included nitrosourea\r\n* Investigational/biological agent: Subjects must have received the last dose of other investigational or biological agent > 7 days prior to study registration; subjects must not have received poly-ICLC in the past\r\n* Radiation therapy (XRT): Subjects must be >= 8 weeks since the completion of radiation therapy\r\n* Study specific limitations on prior therapy: There is no limit on the number of prior treatment regimens or received doses of radiation therapy\r\n* Growth factor(s): Subjects must not have received any hematopoietic growth factors within 7 days of study entry or 21 days for pegfilgrastim\r\n* Prior surgery: Subjects must be >= 2 weeks from prior surgery\r\n* Steroids: Subjects must be on a stable steroid dose for 7 days prior to study entry if they are on steroid treatment
Patients who have received prior taxanes, including weekly taxanes are allowed
Patients who received other chemotherapeutics or investigational agents in addition to their radiation therapy and concomitant temozolomide treatment
Has received prior therapy with an indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibiting agent
Patients may not have received prior cell therapy
Has not received any prior therapy for the disease
Patients must have received < 2 cycles of systemic anti-myeloma therapy.
Patients who have received mid-intensity melphalan (>50 mg IV) as part of prior therapy.
Received prior treatment for cancer with a camptothecin-derived agent.
Received any cell-based anti-AdV therapy within 6 weeks prior to Day 1 or previously received an anti-AdV vaccine at any time.
Patients may have received one prior depot injection of LHRH agonist or LHRH antagonist (degarelix) within 30 days prior to study entry. Patients who have received any other prior hormonal therapy or any chemotherapy for prostate cancer will be excluded. (Patients who have discontinued finasteride or dutasteride or testosterone supplement for at least 2 weeks will be allowed to enroll).
Patients who have received no prior systemic treatment
Has received prior therapy with an immunomodulatory agent.
Patients must not have received zoledronic acid (ZA) for any reason prior to the study
Patients with a confirmed diagnosis of multiple myeloma who have received two or more lines of therapy including an IMiD and PI, and are relapsed and/or refractory to their most recent line of therapy. Patients who have received a prior autologous bone marrow transplant and otherwise meet the inclusion criteria are eligible for this study.
Patients may be treated on this trial without having received prior medical therapy directed at their GIST, patients who have had prior GIST-directed surgery may enroll provided they have measurable disease
Patients who have received previous investigational agents or biologic therapy, such as tipifarnib, pirfenidone, Peg-Intron, sorafenib, imatinib or other targeted therapies are eligible for enrollment; at least 4 weeks must have elapsed since receiving medical therapy directed at the plexiform neurofibromas (PN) and patients who received previous GIST-directed therapy must either demonstrate progression as defined by RECIST, or be unable to tolerate their previous therapy; patients who received prior medical therapy for their PN must have recovered from the acute toxic effects of all prior therapy to =< grade 1 before entering this study
Patients can or cannot have receive prior therapy with hypomethylating agent but will be allocated to specific patient cohorts based on their prior exposure. Patients that had received prior hypomethylating agent therapy should have at least received 6 cycles of therapy and not achieved any response or had progressed after any given number of cycles
Patients may not be receiving or have received Zometa during/or within 3 weeks prior to treatment with Zometa
Received prior obinutuzumab.
Patients who received prior local therapy (e.g., transarterial chemoembolization [TACE]) are eligible
Concurrent treatment with other anti-cancer systemic therapies is not allowed. No other concomitant intrathecal therapy with another agent will be allowed. For patients that have received other systemic therapies, the minimum wash out period is as follows:\r\n* Patients that received previous IT therapy must have received their last treatment >= 14 days prior to the start of treatment\r\n* Patients who have received systemic chemotherapy must have received their last treatment >= 21 days prior to the start of treatment\r\n* Patients who have received an approved biologic therapy (e.g. anti-PD-1, anti-CTLA4, IL2, interferon) must have received their last treatment >= 4 weeks prior to the start of treatment\r\n* Patients who have been treated with an approved targeted therapy (BRAF inhibitor and/or MEK inhibitor) must have received their last treatment >= 28 days or 5 half-lives (whichever is shorter) prior to the start of treatment\r\n* Patients who have received any other investigational agents must have received their last treatment >= 28 days or 5 half-lives (whichever is shorter) prior to the start of treatment
Receiving, or received during the four weeks prior to first dose, cytotoxic treatment for their malignancy Receiving, or received during the week prior to first dose, corticosteroids for any reason
Patients must not have received previous radiation therapy or investigational therapy for the treatment of advanced metastatic disease.
Has received prior anti-myeloma therapy of any type
Patients who received ? 28 days of letrozole or anastrozole for advanced disease prior to inclusion in this trial are eligible.
Insurance pre-authorization must be received
Subjects who have not received radiation therapy as part of their prior treatment are excluded
Has received prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of trial treatment; received thoracic radiation therapy of > 30 Gy within 6 months of the first dose of trial treatment
Participant may have received prior investigational therapy (including immune therapy)
Since there is no standard effective chemotherapy for patients with NF1 and cutaneous neurofibromas, patients may be treated on this trial without having received prior medical therapy directed at their plexiform neurofibromas (PN)
Patients must have received prior radiation therapy and standard temozolomide; patients who have received additional therapies for previous progressions will be considered eligible
Patients must have received one course of induction treatment with BCG (4-6 weekly doses), irrespective of the interval since last treatment; patients are allowed to have received any number of prior chemotherapy instillations\r\n* NOTE: Patients may have received prior intravesical interferon
Subjects must have received or be receiving, at time of enrollment, “RVD” therapy (combination therapy with lenalidomide, bortezomib, and dexamethasone); patients must have received =< 6 cycles of RVD at time of enrollment and must not have progressed (by IMWG criteria) on RVD; patients may have received other regimens prior to RVD if such therapy was limited to =< 3 cycles; patients may have received radiation therapy prior to enrollment; patients must not have received infusional chemotherapy (e.g., bortezomib/thalidomide/dexamethasone-cisplatin/doxorubicin/cyclophosphamide/etoposide [VTD-PACE] or similar regimen) prior to enrollment
Prior treatment:\r\n* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks prior to the start of study drug; however, if they have received nitrosourea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received\r\n* No limitations to number of prior therapies\r\n* Prior treatment with volasertib or any PLK1 inhibitor\r\n* Prior treatment with a histone deacetylase inhibitor (anti-epileptics ok)
Patients who have received organ transplantations.
PRIOR TO LYMPHODEPLETION: Received any investigational agents or received any tumor vaccines within the previous six weeks prior to cell infusion
PRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Received any investigational agents or received any tumor vaccines within the previous six weeks prior to cell infusion
Patients must have received at least one prior therapy for metastatic disease to be eligible
Patients must have received at least one prior therapy for metastatic melanoma
Patients who have received prior radiation therapy for HNSCC
PHASE II:\r\n* Patients must have received at least one course of platinum-based chemotherapy for the management of primary disease including carboplatin, cisplatin, or another organoplatinum compound; this initial treatment may have included intraperitoneal therapy, consolidation, biologic/targeted agents, or extended therapy administered after surgical or non-surgical assessment\r\n* There are no restrictions on the total number of prior regimens patients may have received
Received prior treatment of TAS3681
Subjects who have received prior Doxil and progressed on this therapy are not eligible, but subjects may have received prior doxorubicin.
Any number of lines of prior hormone therapy are allowed\r\n* Patients with clear progression on either tamoxifen or fulvestrant should receive the alternate agent if feasible; if a patient has received both agents in the past, the drug received while on study is at the discretion of the treating physician
Have received CAR-T therapy;
For the phase II portion of the study, patients must be chemo-naive, i.e. not have received any prior chemotherapy (except hydrea or one dose of ara-C [cytarabine] =< 2 g) for AML or MDS; they could have received hypomethylator agents, transfusions, hematopoietic growth factors or vitamins; temporary prior measures such as apheresis or hydrea or one dose of ara-C =< 2 g in order to safely control hyperleucocytosis prior to enrollment
Patients must not have received prior therapy with dasatinib and temsirolimus for any indication
Patients who have received radiation to the spleen within 3 months prior to registration
Unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens; radiation therapy counts as a biologic regimen; patients may not have received radiation therapy to the index lesion within 1 year of enrollment; patients may have tumor spread within the central nervous system (CNS); histologic confirmation of eligibility is required if tissue is available
Patients may not have had prior SGT-53. Patient who have received prior topotecan, cyclophosphamide, or both are eligible.
Study specific limitations on prior therapy:\r\n* Patients who have received poly-ICLC are eligible for this trial if all acute poly-ICLC -related toxicity has resolved\r\n* Patients must not have received pegylated interferon previously
Patients must have received prior external beam radiation therapy to the region proposed for SRS re-irradiation at least 6 months prior to planned re-irradiation\r\n* For patients who were previously treated at an outside institution, adequate records must be available to determine the true dose the cord/cauda received during prior radiation therapy (RT); sufficiency of the treatment records will be assessed and signed-off by the Medical Physics investigator
Patients who have not received any prior treatment
Patient are eligible if they have received one or more prior treatment
Patients must not have received prior bone seeking radionuclides
Received no more than 1 prior treatment for ALL/LBL
Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
Patients who have received prior anti-cancer treatment within the following time frames:\r\n* Received systemic therapies less than 14 days prior to starting on treatment\r\n* Received radiation therapy less than 14 days prior to starting on treatment\r\n* Received biologic therapy less than 14 days prior to starting on treatment
Subjects must not have received medical therapy for any cancer within ONE year prior to registration
Patients must have previously received standard initial therapy, including attempted gross total resection, where safely feasible, and in appropriate circumstances (e.g., those older than one year at initial diagnosis, with non- metastatic tumors and at least microscopic residual disease) involved field fractionated radiation therapy (RT); patients may have received re-irradiation but not to the index lesion within 4 weeks
Patients must not have received prior radiation therapy to the involved breast at any time for any reason
Patients who received cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor; patients who received Gliadel wafers will be excluded; patients may have received or be receiving corticosteroids, analgesics, and other drugs to treat symptoms or prevent complications
Patients are eligible whether they have received or not prior tyrosine kinase inhibitor (TKI) therapy; for the phase I portion of the study, patients who had received prior therapy with dasatinib should have been able to tolerate the dose equivalent to the starting dose of dasatinib in the dose level at which the patient is being entered; patients who previously received dasatinib but never at the dose being proposed are eligible provided they tolerated the maximum dose they were prescribed with no grade 3-4 toxicity not responding to optimal management
Received >360 mg/m2 equivalents of daunorubicin
Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor.
Patient must not have received: cimetidine within 48 hours prior and for the duration of the study
Patients who received > 450 mg/m^2 doxorubicin and have a cardiac ejection fraction on echocardiogram =< 40% on protocol entry are not eligible to received DA-EPOCH-R
Received prior therapy with eribulin mesylate
Patients who have received prior treatment with PTK7-ADC (PF-06647020)
Patients who have received prior immunotherapies
Patient received nitrosureas within 6 weeks prior to the first dose.
Patient received plasmapheresis within 4 weeks prior to the first dose.
Received allogeneic BMT
Histological confirmation of WM for which the patient has received at least one prior treatment; patients may have relapsed or refractory disease;(definition: relapse; patients who have received prior treatment for WM and now have disease recurrence; refractory; patients who have received anti-WM therapy and are noted to have progressive disease while on therapy, or those patients who demonstrated disease progression within 6 months of the last anti-WM treatment)
Patients who have received RAI within 8 weeks
Has received prior therapy with an anti-IDO-1 agent
The subject must have recovered (=< grade 1) from the acute toxic effects of prior therapy\r\n* NOTES: Subjects may have received a single platinum-based cytotoxic chemotherapy regimen; subjects having received prior cytotoxic chemotherapy must have completed their treatment more than 6 months prior to registration; subjects may have received prior therapy with hormones or biologic agents, but such therapies must be discontinued at least 28 days prior to registration for protocol therapy
Patients may have received previous NY ESO 1 vaccine therapy; patients who received bevacizumab or other experimental therapies are eligible for enrollment provided they have discontinued therapy (at least 4 weeks) prior to randomization and recovered from toxicities to less than grade 2
TREATMENT: Patients who have received prior carboplatin or AZD1775 (MK-1775) would not be excluded unless the two drugs were administered in combination; patients who have received prior carboplatin in combination with AZD1775 (MK-1775) would still be eligible to receive other study treatment regimens based on identified genetic mutation(s), other than carboplatin plus AZD1775 (MK-1775)
Patients who have received any tumor-directed therapy prior to biopsy are not eligible; concurrent treatment with corticosteroids is allowed
Patients may have received prior interferon alpha (IFN-alpha), but must not have received IFN-alpha in the 4-week period prior to enrollment on the trial; patients who have not received prior adjuvant therapy should be informed of the potential therapeutic benefit of IFN-alpha; previous radiation therapy, including after the surgical resection, is allowed as long as 14 days have elapsed between the radiation and initiation of first vaccination with NeoVax
Received more than one course of radiation therapy or more than a total dose of 65 Gy. May have received radiosurgery as part of initial therapy; however, the dose counts against the total dose limit.
Patients who have received previous radiation therapy to critical organs exceeding any of the limits shown below, are excluded:
Prior anti-disialoganglioside (GD2) antibody, isotretinoin, or lenalidomide therapy:\r\n* Patients who have received prior anti-GD2 antibody therapy are eligible if they did not have tumor relapse/progression while receiving this therapy\r\n* Patients who have received either isotretinoin or lenalidomide are eligible, but not if they have received the two agents concomitantly
Participants are allowed to have received, but are not required to have received, one\n             additional non-cytotoxic antitumor agent (eg, biologic or cytostatic) for the\n             management of ovarian cancer.
Patients who have received prior immunosuppressive therapy within 30 days prior to enrollment
Patients who have received prior biologic agents less than 30 days prior to enrollment
Arm 2 patients may have an unlimited number of prior therapy regimens but may not have received prior antiangiogenesis therapy except for bevacizumab (patients may not have received aflibercept, ramucirumab, cediranib, cabozantinib, or XL184)
Patients with acute or lymphoma forms must have received at least one cycle of combination chemotherapy (with or without mogamulizumab) or interferon (with or without zidovudine and/or arsenic); individuals with chronic or smoldering acute T-cell lymphoma (ATL) are not required to have had prior treatment or could have received any number of previous courses of therapy
Patients who have received prior therapy with eribulin mesylate are not eligible
Patients who have received prior pulmonary radiation
Patients who have received radiation therapy as part of their leukemia treatment may be ineligible and individual cases must be presented to the study principal investigator (PI) for determination of eligibility
Patients may have received prior bortezomib therapy.
Patient who has received any prior anthracyclines
Received at least one prior treatment with standard therapy (previous antibody\n             therapy is acceptable)
Patients that have received prior radioimmunotherapy
Patients must not have received prior therapy with PF-02341066
Subjects must have received prior antiangiogenic therapy.
Patients must not have received prior chest radiation therapy for NSCLC
Before the first dose of study medication: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease, b) Has received antineoplastic biological therapy (e.g., erlotinib, crizotinib, cetuximab), c) Had major surgery (<3 weeks prior to first dose)
Have received prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones; the participant has received treatment with olaratumab or has participated in a prior olaratumab trial.
Has received prior therapy with vorinostat or other epigenetic agent
Have received prior treatment with everolimus
Patients may have received one or more lines of prior chemotherapy with/without rituximab (including high dose therapy plus stem cell transplant which is counted as one regimen); prior bortezomib is allowed; patients must not have received bortezomib in the past 6 months
Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent
Have received prior radiation to maximally tolerated levels to any critical normal organ
Patients who have received prior therapy with a TLR agonist, excluding topical agents. Patients who have received experimental vaccines or other investigational immune therapies should be discussed with the Medical Monitor to confirm eligibility.
Patients who have received prior capecitabine therapy are not eligible
Patients must not have received any drug that is a moderate or strong inhibitor of 2B6, 2C9, 3A4, and 2C19 within 1 week prior to receiving cyclophosphamide dosing through 72 hours after cyclophosphamide dosing; patients must not have received any drug that is a moderate or strong inducer of 3A4 within 2 weeks prior to cyclophosphamide dosing
Patients who have received prior treatment with GEN-1.
Patients who received other chemotherapeutics or investigational agents in addition to their radiation therapy and concomitant temozolomide treatment
Have received at least one prior therapy for WM
Subjects who have received extensive radiation therapy, including sternum, pelvis, scapulae, vertebrae or skull, within 4 weeks of the first day of study drug or received palliative low dose radiation therapy limited to limbs within 1 week of the first day of study drug, or subjects who have not recovered from side effects of such therapy.
All patients need to have received at least one prior CNS directed therapy; there is no restriction on the number of recurrences
There is no limit on the number or type of prior chemotherapies except:\r\n* Patients must not have received prior treatment with convection enhanced delivery, other catheter based intra-tumoral treatment, or carmustine (BCNU)/Gliadel wafers\r\n* Patients with prior therapy that included stereotactic radiosurgery (including gamma-knife or cyber-knife) during therapy for newly diagnosed or recurrent disease, or re-irradiation of any type, must have confirmation of true progressive disease rather than radiation necrosis based upon surgical documentation of recurrent/progressive disease; imaging with magnetic resonance (MR)Spectroscopy, MRPerfusion, positron emission tomography (PET), or other techniques is not adequate to exclude radiation necrosis for this study\r\n* Patients may not have received prior treatment with an agent designed to inhibit mTOR or PI3K/AKT including, but not limited to, temsirolimus, rapamycin (sirolimus), RAD001 (everolimus), other rapalogs, BKM120, or perifosine; any question regarding the definition of an agent designed to inhibit mTOR or PI3K/AKT targeting should be discussed with the sponsor\r\n* Patients may not have received prior treatment with direct VEGF/VEGFR inhibitors such as bevacizumab (Avastin), aflibercept (VEGF-Trap), cediranib (AZD2171), trebananib (AMG 386), or XL-184 (Cabozantinib)
Patients must have received prior radiation therapy and standard temozolomide
Patients may not have received prior interferon, either systemic or intra-cystic
Patients must not have received prior treatment with pazopanib or topotecan
Patients with colon cancer (cohort A and B) must have received at least 2 prior cancer therapy regimens; patients with other cancer types (cohort C) must have received at least 1 prior cancer therapy regimen; patients in cohort D must have received at least 1 prior cancer therapy regimen; patients must have progressive disease on study entry
Patients who have received =< 1 cycle of therapy after most recent progression/relapse are eligible to enroll on study\r\n* Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted\r\n* Bisphosphonates are permitted\r\n* Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted\r\n* Prior treatment with radiotherapy is permitted\r\n* Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 4 weeks from last dose (on a trial or outside a trial) are eligible
Patients that have received the study medication (Xgeva/Prolia)
Patient must not have received prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5-FU (fluorouracil) therapy
Patients who have received radiation therapy =< 2 weeks prior to study entry; patients who have received prior radiotherapy must have recovered from toxicity (=< grade 1) induced by this treatment
Subjects who received any prior treatment with docetaxel are excluded. Subjects who have received gemcitabine in first line therapy but do not have squamous cell carcinoma, will be eligible as they can receive pemetrexed for the salvage regimen.
Patients must not have received prior therapy other than standard chemoradiation according to Stupp et al and Gliadel
Patients must have been treated with at least one prior treatment regimen that included carboplatin; patients who have received prior radiation therapy for this tumor are eligible
For dose escalation cohorts - subjects who received prior Sunitinib or Pazopanib and required permanent discontinuation due to toxicity or required dose reduction or delay during the first 12 weeks of therapy due to toxicity, or received both prior Sunitinib and Pazopanib
Patients are eligible even if they have not received prior treatment; they are also eligible if they have received prior treatment, and any number of treatments is allowed
Patients must not have received prior Gliadel wafers
Prior therapy: patients with prior history of mediastinal radiation exposure will be ineligible; patients may not have received prior chemotherapy, or antibody therapy for esophageal or GE-junction adenocarcinoma
Received other recent antitumor therapy
Patients who have received prior therapy with ADXS11-001
Received randomized double-blind treatment in PREVAIL;
For Ph+ ALL patients, received corticosteroids within 24 hours before the first dose of ponatinib; or vincristine within 7 days prior to the first dose of ponatinib; or received other chemotherapy within 14 days prior to the first dose of ponatinib.
Glioblastoma disease-specific concerns: Patients must have received cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor; patients who received Gliadel wafers will be excluded; patients may have received or be receiving corticosteroids, AED's, analgesics, and other drugs to treat symptoms or prevent complications
Subject may have received prior investigational therapy (including immune therapy)
Follicular lymphoma patients must have received at least 3 prior lines of therapy; patients are eligible regardless of whether they have received an autologous transplant
Received prior treatment with a hypomethylating agent, except as allowed in Exclusion Criterion 7.b
Patients must not have received prior Gliadel wafers
Patients must not have received systemic chemotherapy or monoclonal antibody therapy within 2 weeks of study enrollment; patients who have previously received bolus nelarabine are still eligible; hydroxyurea or corticosteroids for control of blood counts is allowed, but must be discontinued 24 hours prior to initiating nelarabine
Relapse patients should have NOT received chemotherapy for 4 weeks, and no patient should have received nitrosoureas (melphalan, lomustine [CCNU] or mustard); no patient should have received radiation therapy in the previous 42 days
Patients who received DEPDC1, MPHOSPH1, URLC10, CDCA1, or KOC1 peptide vaccines before
Patients who have received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of the study treatment.
For the phase I portion of the study, patients who had received prior therapy with nilotinib should have been able to tolerate the dose equivalent to the starting dose of nilotinib in the dose level at which the patient is being entered; patients who previously received nilotinib but never at the dose being proposed are eligible provided they tolerated the maximum dose they were prescribed with no grade 3 or 4 toxicity not responding to optimal management
Patients who have received prior immunotherapies
Pts who have received prior mantle or extensive mediastinal radiation
Patients are permitted to have received prior therapy, but must have received a minimum of 30 Gy to the chest wall with a minimal interval since completion of radiation therapy equal to or greater than 6 months; patients who have previously received more than one course of radiotherapy to the breast and/or chest wall OR have received a cumulative dose to the chest wall in excess of 70 Gy will not be considered eligible
Patients who have received prior chemotherapy are allowed, provided they have been off systemic therapy for 21 days and all acute toxicities have resolved to less than grade 2; patients who have received paclitaxel within 3 months of study entry and have developed documented progressive disease despite therapy
Received more than one course of radiation therapy or more than a total dose of 65 Gy. May have received radiosurgery as part of initial therapy; however, dose counts against total dose limit.
Patients who have received prior lenalidomide therapy are not eligible for this study; further there should be at least a 14-day window from the patient’s last prior therapy before initiation of treatment on clinical trial
Received prior HD IL-2 therapy.
Received maintenance Temozolomide
NON-PROGRESSED DIPG (STRATUM 2): Patients must have received a minimum of 54 Gy focal irradiation administered over approximately 42 days prior to enrollment; patients must not have received any other prior therapy for treatment of their central nervous system (CNS) malignancy besides standard radiation therapy
For Part 3, the patient has not received prior treatment with a TKI.
Subjects must have received adequate prior therapy including at a minimum:
Prior therapy with bortezomib is allowed; patients who have received prior bortezomib therapy must have received bortezomib > 6 months ago, and must have shown some response; patients that did not respond to prior bortezomib therapy are not eligible
Patients who have never received radiation to the chest
Have received at least one prior therapy. Patients who are over age 65 and have not received therapy for AML are also eligible, if they are not candidates for induction chemotherapy
Received any prior therapy for lymphoma
Participants must have received at least one prior therapy for FL
Patients has received prior treatment with LEE011.
Received Tivantinib as prior therapy
Received at least 4 weeks of one prior sorafenib containing systemic therapy and then experienced documented radiographic disease progression; or inability to tolerate prior therapy received for at least a minimum period of time.
Received other recent antitumor therapy
Patients who have received prior biologic agents less than 4 weeks prior to enrollment
Patients who have received prior interferon or IL-2 therapy less than 4 weeks prior to enrollment
Must have been receiving or have received crizotinib
Patients who have received prior treatment with cyclophosphamide and topotecan are eligible if they did not have tumor relapse/progression while receiving this combination.
Patients going on Arm 2 must have received planned treatment with radiation therapy and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study; patients must have received at least 80% of planned temozolomide and radiation therapy with no grade 3 or grade 4 toxicity (except lymphopenia) attributed to the temozolomide; Arm 2 patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowed
Patients with NF1 will only be eligible if complete tumor resection is not considered to be feasible without substantial risk or morbidity\r\n* Patients may be treated on this trial without having received prior medical therapy directed at their PN\r\n* There will be no limit to number of prior myelosuppressive regimen for PN or other tumor manifestations associated with NF1 such as optic glioma\r\n* Patients who have received previous investigational agents or biologic therapy, such as tipifarnib, pirfenidone, peginterferon alfa-2b (Peg-Intron), sorafenib, imatinib, or other targeted therapies are eligible for enrollment; at least 4 weeks must have elapsed since receiving medical therapy directed at the PN; patients who received prior medical therapy for their PN must have recovered from the acute toxic effects of all prior therapy to =< grade 1 before entering this study\r\n* Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment\r\n* At least 6 weeks must have elapsed prior to enrollment since the patient received any prior radiation therapy\r\n* At least 4 weeks must have elapsed since any surgeries, with evidence of good wound healing
Patients must have not received any prior therapy other than surgery and/or steroids
Received nitrogen mustard agents, melphalan, or BCNU therapy within 6 weeks prior to the first study dose
Patients must have received adequate prior alkylator therapy
Received investigational therapy or procedure ? 30 days prior to enrollment.
Patients who have received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days and bevacizumab within 28 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of the study treatment
Patients who have received prior Yttrium-90 radioembolization
Subject who received any other systemic anticancer treatment after parent study entry (radiation to local areas such as bone or brain if received in the parent ASP8273 study is permitted).
Patients who have tested positive for a v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation may have received prior BRAF inhibitor therapy as a prior line of systemic therapy; patients may have received up to 2 prior lines of therapy with a checkpoint inhibitor (CPI), which may have included pembrolizumab, nivolumab, or ipilimumab; these agents may have been administered as single-agent treatment, in combination with each other, or in combination with other agents; patients who have received prior treatment with ipilimumab must have relapsed after achieving a response to prior ipilimumab treatment; this response may have been achieved with ipilimumab administered as single-agent therapy or in combination with another treatment; patients who have received prior treatment with pembrolizumab or nivolumab must have progression of disease after at least 4 doses of either drug alone or in combination with other agents
Patients who have previously received anti CD40 (agonistic) therapy prior adjuvant interferon (IFN), is allowed if last dose was received at least 6 months from enrolling to protocol
Subjects who have received prior oncolytic therapy or prior therapy with and toll-like receptor (TLR) agonist including topical agents; subjects that have received experimental vaccines or other immune therapies should be discussed with the medical monitor or the primary investigator (PI) to confirm eligibility
Patients with persistent or recurrent disease must have received definitive chemoradiation therapy as first line therapy; patients with advanced (stage IVB) disease may have received palliative radiation therapy
Prior treatment:\r\n* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks prior to the start of study drug; however, if they have received nitrosourea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received\r\n* No limitations to number of prior therapies\r\n* Prior therapy with other ALK inhibitor investigational agents with the exception of crizotinib (i.e., prior treatment with crizotinib is allowed)
Patients who have received previous cytotoxic chemotherapy including an AC-T regimen or previous therapeutic radiation therapy for any reason in the last 5 years; because of possible limitations in bone marrow reserve, patients with such prior treatments are not appropriate candidates for this trial; patients who have had prior hormonal therapy (for instance, tamoxifen for prevention of breast cancer) are eligible; patients who have participated in a window study (treatment with an investigational agent prior to surgery for =< 2 weeks) are eligible but must have discontinued the investigational agent at least 14 days before enrollment
Subject has received prior therapy with a BH3 mimetic.
Patients must not have received prior treatment with talimogene laherparepvec (T-VEC) or other oncolytic virus agents
Has received voriconazole within 5 days prior to starting study therapy
Has received the full dose of CTX over the course of their treatment
Have received at least one prior therapy for WM
Patients who have received chemotherapy within 3 weeks of first fenretinide treatment, or who have received investigational drugs within 6 weeks of first fenretinide treatment. Patients must have otherwise recovered from toxicities of prior therapy.
Received Pap test within ONE year
Received any investigational agents or received any tumor vaccines within the previous six weeks prior to cell infusion
Has received any formulation of POS within prior 10 days
Patients who have received prior romidepsin use are eligible
Patients who have received no prior therapy are eligible, as well as those who have received prior treatment
Participants who received biopsy only or have received more than 2 prior courses of radiation for meningioma
Women should have received no prior therapy for their disease
Participants with HCC must have received prior sorafenib therapy. ICC participants must have received prior platinum (cisplatin or oxaliplatin) based therapy unless contraindicated.
Subjects must not have received BLZ-100 within 30 days prior to re-treatment
Subjects must have received adequate prior therapy including at a minimum: